Amgen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
Extension Study of Etelcalcetide for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on Hemodialysis
- First Posted Date
- 2014-04-02
- Last Posted Date
- 2017-11-17
- Lead Sponsor
- Amgen
- Target Recruit Count
- 902
- Registration Number
- NCT02102204
- Locations
- 🇹🇷
Research Site, Izmir, Turkey
A Phase 1/2 Study Evaluating AMG 337 in Asian Subjects
- First Posted Date
- 2014-03-26
- Last Posted Date
- 2021-12-28
- Lead Sponsor
- Amgen
- Target Recruit Count
- 11
- Registration Number
- NCT02096666
- Locations
- 🇯🇵
Research Site, Suntou-gun, Shizuoka, Japan
A Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-02-27
- Last Posted Date
- 2017-05-02
- Lead Sponsor
- Amgen
- Target Recruit Count
- 9
- Registration Number
- NCT02072863
- Locations
- 🇮🇹
Hospital City of Health and Science of Turin, Hematology 1 Division, Turin, Italy
🇮🇹Ospedale Oncologico Regionale, Rionero in Vulture, Potenza, Italy
🇳🇱Erasmus MC, Department of Hematology, Rotterdam, Netherlands
Bioequivalence Study of Denosumab CP4 Drug Product and Commercially Available Denosumab CP2 Drug Product
- First Posted Date
- 2014-02-04
- Last Posted Date
- 2017-12-29
- Lead Sponsor
- Amgen
- Target Recruit Count
- 146
- Registration Number
- NCT02053753
- Locations
- 🇺🇸
Research Site, San Antonio, Texas, United States
Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2013-12-17
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- Amgen
- Target Recruit Count
- 405
- Registration Number
- NCT02013167
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
Retrospective Analysis of Survival in Adult MRD Positive Acute Lymphoblastic Leukemia Patients
Completed
- Conditions
- First Posted Date
- 2013-12-13
- Last Posted Date
- 2022-09-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 310
- Registration Number
- NCT02010931
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Historical Data Analysis of Hematological Remission and Survival in Adults With R/R Acute Lymphoblastic Leukemia
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-12-06
- Last Posted Date
- 2022-11-07
- Lead Sponsor
- Amgen
- Target Recruit Count
- 2373
- Registration Number
- NCT02003612
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Blinatumomab in Adults With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-12-04
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Amgen
- Target Recruit Count
- 45
- Registration Number
- NCT02000427
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
Efficacy, Safety and Tolerability of Romosozumab in the Treatment of Japanese Women With Postmenopausal Osteoporosis
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2019-03-25
- Lead Sponsor
- Amgen
- Target Recruit Count
- 252
- Registration Number
- NCT01992159
- Locations
- 🇯🇵
Research Site, Toshima-ku, Tokyo, Japan
Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-11-14
- Last Posted Date
- 2018-11-29
- Lead Sponsor
- Amgen
- Target Recruit Count
- 511
- Registration Number
- NCT01984424
- Locations
- 🇬🇧
Research Site, Newcastle upon Tyne, United Kingdom
© Copyright 2024. All Rights Reserved by MedPath